GERN Geron Corporation
$0.88▼ -6.83%
Healthcare
Other
Volume 13.99M
Avg Volume (10D) 17.16M
Key Metrics & Fundamentals
Market Cap
$566.40M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.84 - 2.01
% vs 50 MA
-27.46%
% vs 200 MA
-33.72%
RSI-14
24.8
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.26
Free Cash Flow
-$16.05M
Gross Rev
$57.48M
Gross Profit
$48.24M
EBITDA
-$9.36M
COGS
$9.24M
Operating Exp
$60.89M
Operating Income
-$12.65M
EBIT
-$12.65M
Pretax Income
-$16.68M
Net Income
-$16.68M
EPS (Diluted)
-0.02
Price & Volume History
Loading chart…
Recent News
Geron winds down Phase III rare blood cancer trial after muted efficacy
Clinical Trials Arena · Oct 30, 2026 8:11 AM ET
Geron's Core Rytelo Business Remains on Track Despite Trial Halt, Wedbush Says
MT Newswires · Oct 28, 2026 12:33 PM ET
BC-Most Active Stocks
Associated Press · Oct 28, 2026 10:30 AM ET
Geron Discontinues Phase 3 Trial Evaluating Imetelstat in Myelofibrosis
MT Newswires · Oct 28, 2026 10:11 AM ET
Wedbush Adjusts Price Target on Geron to $5 From $6, Keeps Outperform Rating
MT Newswires · Oct 28, 2026 9:51 AM ET
Geron stock tumbles after halting Phase 3 trial
Investing.com · Oct 28, 2026 8:56 AM ET
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
GlobeNewswire · Oct 28, 2026 8:00 AM ET
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire · Oct 21, 2026 8:00 AM ET
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 19, 2026 4:01 PM ET
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
GlobeNewswire · Oct 12, 2026 8:03 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See GERN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.